Elevating Patient Care: Managing Patients With Neurotrophic Keratitis: Improve outcomes through recognition, applying updated staging, evidence-based treatment and team-based follow-up

To participate in this activity, please:

The treatment of patients with neurotrophic keratitis, a rare disease of the eye that can lead to blindness, has evolved beyond treating symptoms to treatment that targets the root cause of the disease – nerve damage. Thus, early diagnosis is critical. The interprofessional faculty share their real-world experience as they discuss the etiology, diagnosis, staging, and treatment of patients with neurotrophic keratitis. In addition to an overview of symptomatic care and emerging treatments, the safety, efficacy, storage, and administration of cenegermin are explained in detail. Clinical and real-world questions are discussed, related to patient education, provided by the interprofessional, multidisciplinary team.

This activity is also available as a podcast: You may listen here

Course Credit:

1 AAPA Category I Hour
1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.25 Pharmacology Hours

Dates:

Opens: 2024-06-07
Closes: 2025-06-07

Target Audience:

This activity was developed for ophthalmologists, optometrists, and other clinicians who care for patients with corneal diseases.

This activity is supported by an educational grant from Dompé.

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1 hour . Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 hour AAPA Category 1 CME credits. Approval is valid until June 07, 2025. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1 ANCC contact hour, including 0.25 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Tim Drake, PharmD, MBA, BCPS (Medical Writer)
No significant relationships to disclose.

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Kenneth A. Beckman, MD, FACS

    Comprehensive EyeCare of Central Ohio, Westerville, Ohio
    The Ohio State University
    Columbus, Ohio

  • Stephanie L. Conway-Allen, PharmD, RPh

    Associate Professor of Pharmacy Practice
    Massachusetts College of Pharmacy and Health Sciences
    Worcester, Massachusetts

  • Preeya K. Gupta, MD

    Managing Director, Triangle Eye Consultants
    Raleigh, North Carolina
    Adjunct Associate Professor of Ophthalmology,
    Tulane University School of Medicine
    New Orleans, Louisiana

Learning Objectives

  • Distinguish the unique signs and symptoms associated with neurotrophic keratitis (NK)
  • Explain the diagnostic criteria necessary for NK
  • Employ evidence-based strategies for treating patients with NK
  • Collaborate and communicate with other healthcare team members to provide patient education and ensure appropriate treatment and follow-up for NK

Faculty Disclosures

Kenneth A. Beckman, MD, FACS

Advisory Board: Ocular Science

Consultant: AbbVie, Alcon, Amgen, Bausch & Lomb, BioTissue, Dompé, Glint, Novaliq, Sinqi Pharma, Sun, Thea, Trukera, Versea, Yuyu Pharma

Ownership: Comprehensive EyeCare of Central Ohio


Stephanie L. Conway-Allen, PharmD, RPh

No relationships to disclose.

Preeya K. Gupta, MD

Consultant: Azura, Alcon, Aldeyra, Allergan, Amring, Dompé, Expert Opinion, HanAll Biopharma, J&J Vision, Kala, New World Medical, Novartis, Ocular Science, Ocular Therapeutix, Orasis, Oyster Point, Sight Sciences, Spyglass, Surface Ophthalmics, Sun Pharmaceuticals, Tear Lab, Tear Clear, Tissue Tech, Inc., Trukera